Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) in a research report report published on Wednesday, PriceTargets.com reports. Several other equities research analysts have also issued reports on the company. StockNews.com assumed coverage on Rocket Pharmaceuticals in a research report on Thursday, March 16th. They set a sell […]

Related Keywords

United States ,America ,Jonathan David Schwartz ,William Blair ,Gaurav Shah ,Insider Activity At Rocket Pharmaceuticals ,Rocket Pharmaceuticals Inc ,Analyst Recommendations For Rocket Pharmaceuticals ,Needham Company ,Nasdaq ,Institutional Investors Weigh In On Rocket Pharmaceuticals ,Life Insurance Co ,Kiwi Wealth Investments Limited Partnership ,Rocket Pharmaceuticals ,Rocket Pharmaceuticals Stock Down ,Metlife Investment Management ,Steward Partners Investment Advisory ,News Ratings For Rocket Pharmaceuticals Daily ,Get Rating ,Moderate Buy ,Pharmaceuticals Stock Down ,Life Investment Management ,Partners Investment Advisory ,Rocket Pharmaceuticals Daily ,Nasdaq Rckt ,Rckt ,Medical ,Reiterated Rating ,